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More than 60 years ago, Otto Warburg showed that cancer
cells exhibit enhanced glycolysis accompanied by greatly
elevated levels of lactate secretion, even in the presence of
normal levels of oxygen (1). Warburg suggested that cancer
cells arise from normal cells in a two-phase process: phase 1
is “injury” to the respiratory machinery (i.e., mitochondria),
followed in phase 2 by enhanced “fermentation” (i.e.,
production of lactate from glucose) in the protoplasm (i.e.,
cytosol) (1). Conversion of glucose to lactate as a source
of ATP is very inefficient compared to that obtained by
complete oxidation of glucose to CO2 via tight coupling of
glycolysis to the mitochondrial TCA cycle. Nevertheless,
Warburg suggested that given ready access to adequate
circulating glucose “fermentation” can provide quiescent
cancer cells with the necessary energy requirements (1). For
many years the Warburg effect was treated mainly as just
another interesting biochemical phenomenon. However,
within the last decade the “Warburg effect” has become
the subject of intense investigation. We now know that the
mitochondria in many cancer cells are not grossly defective
as originally envisaged by Warburg, but are metabolically
reprogrammed (2). In this case, the carbon of certain
metabolites can enter the TCA cycle (anaplerosis) as both an
energy source and as a source of intracellular components
(e.g., for lipids, nucleic acids, proteins) necessary for rapidly
dividing cells. An especially important metabolite in this
regard is glutamine (3). Rapidly dividing cancer cells that
require substantial amounts of glutamine are said to exhibit
“glutamine addiction”. Glutamine is readily converted to
the TCA cycle intermediate α-ketoglutarate (α-KG) while
at the same time providing nitrogen for DNA, polyamine
© Translational Cancer Research. All rights reserved.

and non-essential amino acid synthesis. Glutamine is
converted to α-KG in a two-step process. Glutamine is
hydrolyzed to glutamate by glutaminase, which in turn
is converted to α-KG by the glutamate dehydrogenase
reaction or by transamination with a suitable α-keto acid
substrate (4).
The importance of the Warburg effect and glutamine
metabolism in cancer cells was elegantly demonstrated by
DeBerardinis et al. (5). These authors used 13C-glucose
coupled to 13C-NMR to show that glioblastoma cells in
culture copiously convert glucose to lactate (and, to a lesser
extent alanine) in the presence of oxygen. Moreover, using
13
C-glutamine the authors showed that glutamine is also
an important energy source in these cells (glutaminolysis).
In these studies, a substantial portion of glutamine carbon
(60%) was shown to be directed toward lactate production.
DeBerardinis et al. state “A by-product of this flux is robust
NADPH production by malic enzyme. The glutaminolytic flux
was at least as high as the G6PDH flux, and appeared to be
higher than that needed for fatty acid synthesis. This could mean
that NADPH generated during glutaminolysis also supplies other
anabolic processes such as nucleotide biosynthesis.” Interestingly,
glutamine nitrogen was lost to the medium not only
as alanine but also as ammonia. Apparently, although
glutamine is a source of nitrogen for many compounds in
the glioblastoma cells the utilization of glutamine carbon
through the TCA cycle provides nitrogen in excess of that
needed for these biosynthetic reactions and is excreted in
the form of alanine and ammonia (5).
A crucial enzyme in the glutaminolysis pathway is
glutaminase (6). In mammals, GLS and GLS2 genes encode
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two glutaminase isozymes. GLS encodes a kidney-type
glutaminase (GLS) and a splice variant [glutaminase C
(GAC)]. GLS2 encodes a liver-type glutaminase (GLS2)
and a splice variant [glutaminase B (GAB)] (7). Thus, it
is not surprising that several cellular oncogenes and their
signaling pathways regulate glutaminase activity in cancer
cells. For example, many cancer cells that express high
levels of c-Myc exhibit elevated glutaminase activity (8),
which is associated with de-repression of glutaminase by the
microRNA mir23a/b (9). Thus, a molecular link between an
oncogenic signal and elevated glutaminase activity has been
established. However, this link is not unique to cancer cells
because several non-cancerous diseases, such as pulmonary
hypertension are also associated with increased glutamine
metabolism in the affected cells (10). Because of the unique
role of glutaminase in disease processes, intense efforts
have been directed toward the development of selective and
potent glutaminase inhibitors.
One such glutaminase inhibitor was identified by Wang et al.
as a brominated phenanthridinone derivative (compound 968),
which was discovered during a chemical screen for inhibitors
of a class of oncogenic signaling proteins, namely Rho
GTPases (11). In this study, the compound was found to: (I)
block oncogenic transformation induced by a well-known
guanine nucleotide exchange factor in fibroblasts; and (II)
block the growth of human breast cancer and B lymphoma
cells, without affecting normal cells (11). A biotinylated
derivative of compound 968, when used in a streptavidin
pull-down assay revealed that its target protein is the
mitochondrial glutaminase (GLS) (11). Additional studies
by Wang et al. showed specific down-regulation of GLS by
siRNA is associated with suppression of colony formation of
cells that constitutively express the oncogenic Rho GTPase
family member diffuse B-cell lymphoma (dbl) (11). Further
studies revealed that glutaminase inhibition strongly
suppresses breast cancer cell proliferation and confirmed a
molecular link between elevated glutaminase activity and
oncogenic transformation of cells that express Rho GTPase
family members (11). The increase in glutaminase activity
in these cells was also found to depend on the expression of
NF-κB (11). Interestingly, these studies also revealed that
the inhibitory effect of the compound 968 could be partially
reversed by the supplementation with α-KG, a metabolite
in the TCA cycle downstream of GLS activity. Thus, these
studies established the importance of glutaminase activity
in cancer cells along with its importance in the anaplerotic
provision of the TCA cycle intermediate α-KG in cancer
cell growth.

A follow-up of the study by Wang et al. (11) by the same
group (and the subject of the current commentary) provides
a mechanistic link between the action of Rho GTPases and
the elevation of glutaminase activity (7). In these studies
another potent inhibitor of GLS/GAC was used, namely
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide
(BPTES). In this study, Lukey et al. concluded that: (I) the
oncogenic transcription factor c-Jun is responsible for the
elevation of glutaminase activity by Rho GTPase family
members; (II) c-Jun is an important regulator of GLS
expression in human breast cancer; and (III) overexpression
of this cellular proto-oncogene is sufficient to sensitize
breast cancer cells to glutaminase-targeted therapy. Thus,
these studies are further confirmation of the importance
of glutaminase activity as an important step in providing
anaplerotic α-KG, critical for cancer cell growth.
These findings are significant for the following reasons:
first, they highlight the contribution of the protein product
of the oncogene c-JUN, (which is overexpressed and/or
stabilized in many cancers, including breast cancer) in the
metabolic rewiring of cancers and provide a molecular
explanation for the increased dependency on glutamine
metabolism. Second, they offer an explanation for the
coordinated metabolic reprogramming and signaling that
is required for concomitant increases in cell proliferation
and biomass. Finally, elevated expression of GLS in triple
negative breast cancer (TNBC), as opposed to estrogen
receptor positive (ER+) breast cancer, is now known to be
associated with an increase in the protein levels of both
proto-oncogenes c-JUN and c-MYC, which transcriptionally
upregulate GLS mRNA (12,13). Thus, targeting GLS in
TNBC is the basis for several currently ongoing clinical
trials.
Despite advances in our understanding of the overall
importance of glutaminase activity in cancer metabolism,
there are still some unresolved issues. First, whereas GLS
is upregulated by several oncogenes such as c-MYC and
c-JUN, GLS2 is upregulated by the tumor suppressor
protein p53 (14,15). Although wild type p53 contributes to
the upregulation of glutaminase it has the added property
of promoting antioxidant activity through the increased
production of glutathione, which in turn is associated
with a significant reduction in tumor development. Thus,
Myc- or Jun-induced glutaminolysis supports cancer
cell proliferation, whereas p53-induced glutaminolysis is
associated with tumor suppression. Hence, there is a need
for the design of: (I) compounds that inhibit GLS but not
GLS2; and (II) compounds that activate GLS2. In this
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respect, strategies that are aimed to rescue mutant p53
(which is expressed in a significant fraction of solid tumors)
and restore its normal function (16) gain more significance,
namely their role in reprogramming of glutamine
metabolism for cancer therapeutic purposes.
Second, the recent report by Lukey et al. emphasizes
the role of c-Jun signaling downstream of the Rho
GTPase activation in the upregulation of glutaminase
activity (7). Earlier work by the same group highlights the
importance of NF-κB signaling downstream of the same
family of Rho GTPases (11). It is interesting to note that
mutated p53 stimulates the mevalonate pathway, which
provides the geranylgeranyl pyrophosphate moieties
covalently linked to Rho family members for insertion
into membranes, contributing to their activation (17).
By contrast, as described above, wild type p53 enhances
GLS2 expression (14,15). The use of glutamine either in
normal cell function or in proliferation mirrors the ability
of p53 to induce or suppress reactive oxygen species (ROS)
production. More importantly, GLS is upregulated by the
cellular oncogene c-MYC, which negatively controls the
glutaminase-suppressing microRNA, miR23a/b (9). The
cellular oncogene c-SRC, which was the first tyrosine kinase
oncogene to be discovered, also regulates glutaminase
metabolism indirectly through c-MYC. In a recent study, Jain
et al. showed that SRC blockade reduces glucose metabolism
and the Warburg effect in breast cancer cells through the
inhibition of extracellular signal regulated kinase (ERK)1/2MNK1-eIF4E-mediated cap-dependent translation
of c-MYC and the glucose transporter GLUT1 (18).
In addition, Src is known to activate the Rho GTPase Rac1
through the participation of the adaptor oncogene CRKII
and p120 catenin (19,20). These observations suggest
that Rho GTPases activate the Jun N-terminal kinase
(JNK), which, in turn, phosphorylates c-Jun, thus strongly
activating its properties as a transcription factor. Moreover,
evidence suggests the participation of the proliferation/
angiogenesis and metastasis suppressor protein SSeCKS
(pronounced Essex) [Src suppressed C-kinase substrate;
a member of the myristoylated alanine-rich C-kinase
substrate (MARCKS) family] in the control of signaling
pathways in oncogenesis (21). We propose a hypothesis that
integrates the activities of several oncogenes and the tumor
suppressor gene p53 (Figure 1). However, the major tenet
of this hypothesis, namely the involvement of SSeCKS or
MARCKS family of proteins needs to be verified. MARCKS
and related SSeCKS proteins serve as a reversible source of
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phosphoinositides (particularly PIP2), sequestering them
in the plasma membrane and preventing their conversion
into PIP3. This sequestration inactivates phosphoinositidedependent kinase (PDK) thus attenuating PI 3-kinase and
Akt (22). SSeCKS, which is also known as AKAP12 or
gravin, functions as a tumor and metastasis suppressor (23).
Recent studies have shown that the functions of SSeCKS/
AKAP12 likely involve its ability to negatively influence
specific oncogenic signaling pathways through the
scaffolding of key mitogenic mediators such as PKC, PKA,
cyclins and calmodulin by an electrostatic switch mechanism
acting at the membrane (24). Conversely, loss of SSeCKS
activity, either by down-regulated gene expression or by
phosphorylation leads to hyperactivated PKC-isoenzymes,
which in turn leads to increased invasiveness in prostate
cancer cells (25).
Studies by Gelman and coworkers (23) clearly establish
the suppressive role of SSeCKS in Src-induced oncogenesis
by regulating the Rho GTPase family members, namely
RhoA- and Cdc42-dependent pathways. Since SSeCKS/
AKAP12 controls cellular events that cause scaffolding of
key signaling molecules such as cyclin D1, calmodulin,
PKA, and PKC, this effect would help re-establish the
actin-based cytoskeletal architecture (23). Additionally,
c-JNK phosphorylation of the MARCKS family member
MARCKSL1 determines actin stability, cytoskeletal
structure and cell movement, which are important for
cancer cell invasiveness, as shown in a prostate cancer
model system (26). Working along similar lines, Cohen
and coworkers have shown that forced re-expression of
the down-regulated SSeCKS reversed the v-Jun induced
transformation of 10T1/2 murine fibroblasts (27). These
observations suggest that: (I) there is a nexus of regulatory
signaling pathways connecting PKC and Rho GTPases
to the SSeCKS protein, leading to its down-regulation
in cancer; and (II) a down-regulation of SSeCKS is a
requirement of v-Jun-induced oncogenic transformation.
The oncogenic v-Jun protein differs from c-Jun by two
amino-acid substitutions in the C-terminal DNA binding
domain and an N-terminal 27 amino acid deletion. Hence,
it is very likely that down-regulation of SSeCKS is also an
oncogenic pre-requisite for c-Jun-overexpressing cancer
cells, including human cancers. Cohen and colleagues (27)
have also shown that SSeCKS functions as a tumor
suppressor, counteracting the oncogenic effect of Jun as well
as Src. Thus, it will be very interesting to determine how
Rho GTPase family members that activate JNK negatively
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Figure 1 Proposed convergence of signaling pathways from several oncogenes and tumor suppressor gene p53 to reprogram glutamine
metabolism. An integrated view of the participation of Src, Myc, NF-κB, c-Jun and p53 proteins is presented. Glutaminase (kidney type,
GLS) is upregulated by multiple oncogenic transcription factors, such as c-Myc, c-Src and c-Jun. In addition, wild type p53 transcriptionally
upregulates the liver type glutaminase (GLS2) stimulating potent anti-tumorigenic and anti-oxidant properties of the cell. Intriguingly,
mutant p53 activates the oncogenic Rho GTPases by providing the necessary membrane anchor (the geranylgeranyl moiety) derived from
the mevalonate pathway. Several PKC enzymes associate with Rho GTPases in their activation of Jun kinase activity [Jun N-terminal kinase
(JNK)]. In the proposed unifying hypothesis, these proteins act in concert to down-regulate or inactivate (by phosphorylation) the scaffolding
protein SSeCKS of the myristoylated alanine-rich C-kinase substrate (MARCKS) family of proteins and this down-regulation is linked to
an up-regulation of JNK activity, thus enhancing the phosphorylation of the oncogenic transcription factor c-Jun. In the publication serving
as the basis for the present commentary, Lukey et al. showed that c-Jun is the transcription factor that is activated by phosphorylation,
which subsequently binds to the kidney type glutaminase (GLS) promoter and upregulates the expression of GLS, thereby reprogramming
glutamine metabolism in cancer cells. Thus, the expression/activity of MARCKS/SSeCKS and the activity of the transcription factor c-Jun
are proposed to be inversely related. Incidentally, the Rho family of proteins and the MARCKS proteins are implicated in the release of large
extracellular vesicles, which may explain the dual role of GTPase regulation in the reprogramming of glutamine metabolism as well as in
the alteration of the cytoskeletal architecture necessary for vesicle release. Importantly, this may give a molecular explanation for the genesis
of cancer cell dormancy (see the text for details). The signaling pathway where the hypothesized connection to the MARCKS/SSeCKS
proteins is made is denoted by a question mark (?). It is possible that glutamine positively regulates RhoA and JNK directly as shown by
an intense blue arrow in the figure which would then set up a vicious cycle wherein glutamine facilitates its own hydrolysis, a phenomenon
which could be co-opted by the cancer cells for highly demanding proliferative purposes. It is also possible that glutamine directly activates
RhoA expression and activity, as shown by the intense green arrows in the figure. See text for details.
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influence the expression of MARCKS or related SSeCKS
proteins. This may provide a molecular explanation for the
mechanism by which Rho GTPases activate JNK, which
in turn activates c-JUN specific transcription, providing
a molecular link to the studies by Lukey et al. (7). Several
pieces of indirect evidence suggest the participation of
proteins such as MARCKS in the activation of JNK. For
example, one study showed that the MARCKS protein
regulates the expression of pro-inflammatory cytokines in
murine macrophages through the activation of JNK and
NF-κB (28). It is worth noting in this context that SSeCKS,
MARCKS and the extracellular matrix protein SPARC are
down-regulated in v-Jun transformed cells (29). Thus, it
is very likely that in human cancers over-expressing c-Jun,
the same genes such as SSeCKS and MARCKS may be
targeted for negative regulation. These studies suggest that
a molecular relationship may exist between Rho GTPases
and elevated JNK signaling (leading to c-JUN activation),
and that the MARCKS/SSeCKS family of proteins may
provide the link connecting the two (Figure 1). Therefore, it
would be very interesting to determine the expression levels
of MARCKS/SSeCKS and whether a re-expression or overexpression of MARCKS or SSeCKS negatively influences
glutaminase expression as seen in the experimental system
employed by Lukey et al. (7).
Third, Lukey et al. have shown that a cell-permeable
α-KG precursor partially rescues the growth of dblexpressing mouse embryonic fibroblasts (MEFs) (7).
This raises the immediate concern that cancer cells that
reprogram metabolic pathways and elevate intracellular
α-KG will negate the therapeutic potential of glutaminasetargeted therapies currently under investigation. Several
bypass mechanisms for obtaining anaplerotic carbon are
potentially available to the cancer cell and it would be
important to investigate their participation before clinically
testing any anti-glutaminase therapies.
Fourth, it is interesting to note that an important
connection between RhoA-mediated elevation of glutaminase
and the generation of large extracellular vesicles has been
observed in cancer cells (30). Notably, introduction of specific
glutaminase inhibitors (compound 968 or BPTES) strongly
inhibits the shedding of these large extracellular vesicles in a
variety of cancers such as glioblastoma, metastatic mammary
gland adenocarcinoma, pancreatic ductal carcinoma, and
pancreatic adenocarcinoma (31).
Thus, it appears that reprogramming of glutamine
metabolism and elevated glutaminase activity meet the
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metabolic demands for increased biomass and lipid
synthesis required to replace the plasma membranes lost
from these cancer cells as extraverted vesicles. In this
respect, it is intriguing that, in a recent study, exosomes
from bone marrow mesenchymal cells were shown to
contain a microRNA (miR23b) directed against MARCKS
mRNA that promotes dormancy in metastatic breast
cancer cells (32). Apparently, breast cancer cells fuse with
vesicles containing miR23b, inducing suppression of
the gene MARCKS. This observation has at least three
important implications. First, the miR23b when taken
up by the target cancer cells may also down-regulate the
expression of GLS, thus preventing the reprogramming of
glutamine metabolism, which is crucially needed for cell
proliferation and increased metabolic demands. Second,
suppressing glutamine metabolism (in the absence of the
c-Myc signal) may promote cancer cell dormancy, such as
in micrometastases. An increase in GLS may then function
as a “wake up” signal for dormant cancer cells to emerge
as a proliferating cancer cell. Third, the observation that
miR23b also targets MARCKS protein along with GLS
strongly supports the hypothesis (Figure 1) that MARCKS/
SSeCKS integrates in the Rho GTPases/GLS regulatory
mechanism.
Fifth, glutamine is the most abundant free amino acid
in the body and is well known to play a regulatory role in
several cell specific processes such as apoptosis and cell
proliferation (33). Glutamine also has a role in activating
metabolism, signal transducing and redox processes, and
in stimulating gluconeogenesis, lipogenesis, extracellular
matrix production, respiratory burst/cell defenses and heat
shock response/chaperone functions (33). Thus, the function
of glutamine transcends its classical roles as a simple building
block for proteins, a metabolic fuel and a nitrogen source for
various biomolecules. Importantly, glutamine plays a role in
potentiating the effects of growth factors that facilitate gene
expression, cell proliferation and repair (34). In this regard,
Rhoads et al. have shown that glutamine activates both
extracellular ERK and JNK in intestinal cell proliferation.
These proteins are involved in signal transduction pathways
stimulated by growth factors, resulting in an increase in
AP-1-dependent gene transcription and c-Jun mRNA levels,
positively regulating the expression of genes involved in cell
division (35). Moreover, glutamine activates the mTORC1
cell proliferation pathway both directly and indirectly
through the import of leucine through a bidirectional
transport mechanism (36). Therefore, while the studies
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by Lukey et al. (7) have focused on GLS activity, it is also
possible that glutamine per se may have a direct effect
in activating JNK under certain cellular circumstances.
In consideration of this direct effect, a vicious circle
of events may occur wherein glutamine activates JNK,
JNK phosphorylates c-Jun, and phosphorylated-c-Jun
translocates to the nucleus and activates transcription of
GLS. The resultant GLS translocates to the mitochondria
where it catalyzes the hydrolysis of glutamine to glutamate
and ammonium. Interestingly, a recent report shows that
glutamine and its dipeptide analog alanyl-glutamine can
increase RhoA expression in intestinal epithelial cells (37).
Therefore, future investigations must take into account the
participation of glutamine in activating its own metabolism,
a phenomenon that could be exploited by cancer cells
through Rho GTPases. These observations not only
highlight the importance of the studies by Lukey et al. (7)
in contributing to our understanding of individual signaling
processes involved in the glutamine addiction of cancer
cells, but also support the hypothesis that several signaling
pathways converge synergistically in this process (Figure 1).
Finally, several very recent reports indicate that the
“glutamine addiction” observed in several cancer cell lines
in culture is not exactly reproduced in vivo, suggesting that
the tumor microenvironment may play an important role in
the reprogramming of glutamine metabolism and hence the
metabolic phenotype (38,39). Thus, within the core of the
tumor, metabolic heterogeneity may exist with respect to
glutamine dependency, which may or may not be sensitive
to glutaminase-targeted therapies (38-40). This raises
question of how the c-Jun activated pathways are regulated
by gradients in nutrient concentrations within the highly
perfused and poorly perfused regions of the same tumor.
In conclusion, additional studies are needed to
evaluate and interpret the therapeutic potential of
glutaminase inhibitors, especially within cancers that have
reprogrammed glutamine metabolism. Lastly, a better
understanding of the Warburg effect is beginning to emerge
with regard to the metabolic influences of glutaminase.
The paper by Lukey et al. is timely and significant since it
focuses on the role of altered oncogenic signaling pathways
in the rewiring of cancer cell metabolism and should lay the
foundation for personalized and targeted therapy of cancer
patients, based on their metabolic phenotype.
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criticisms.

Acknowledgements
The authors wish to thank Irwin H. Gelman (Roswell

© Translational Cancer Research. All rights reserved.

Footnote
Provenance: This is a Guest Commentary commissioned
by the Section Editor Decai Yu (Hepatobiliary Institute of
Nanjing University, Department of Hepatobiliary Surgery,
Drum Tower Hospital, The Affiliated Medical School of
Nanjing University, Nanjing, China).
Conflicts of Interest: The authors have no conflicts of interest
to declare.
Comment on: Lukey MJ, Greene KS, Erickson JW, et al. The
oncogenic transcription factor c-Jun regulates glutaminase
expression and sensitizes cells to glutaminase-targeted
therapy. Nat Commun 2016;7:11321.
References
1.

Warburg O. On the origin of cancer cells. Science
1956;123:309-14.
2. Ward PS, Thompson CB. Metabolic reprogramming: a
cancer hallmark even warburg did not anticipate. Cancer
Cell 2012;21:297-308.
3. Ahn CS, Metallo CM. Mitochondria as biosynthetic
factories for cancer proliferation. Cancer Metab 2015;3:1.
4. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell
metabolism. Nat Rev Cancer 2011;11:85-95.
5. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond
aerobic glycolysis: transformed cells can engage in
glutamine metabolism that exceeds the requirement for
protein and nucleotide synthesis. Proc Natl Acad Sci U S
A 2007;104:19345-50.
6. Szeliga M, Obara-Michlewska M. Glutamine in neoplastic
cells: focus on the expression and roles of glutaminases.
Neurochem Int 2009;55:71-5.
7. Lukey MJ, Greene KS, Erickson JW, et al. The oncogenic
transcription factor c-Jun regulates glutaminase expression
and sensitizes cells to glutaminase-targeted therapy. Nat
Commun 2016;7:11321.
8. Dang CV. MYC on the path to cancer. Cell 2012;149:22-35.
9. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc
suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature
2009;458:762-5.
10. Piao L, Fang YH, Parikh K, et al. Cardiac glutaminolysis:
a maladaptive cancer metabolism pathway in the right

tcr.amegroups.com

Transl Cancer Res 2016;5(S2):S349-S356

Translational Cancer Research, Vol 5, Suppl 2 August 2016

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

ventricle in pulmonary hypertension. J Mol Med (Berl)
2013;91:1185-97.
Wang JB, Erickson JW, Fuji R, et al. Targeting
mitochondrial glutaminase activity inhibits oncogenic
transformation. Cancer Cell 2010;18:207-19.
Wang X, Chao L, Li X, et al. Elevated expression of
phosphorylated c-Jun NH2-terminal kinase in basallike and "triple-negative" breast cancers. Hum Pathol
2010;41:401-6.
Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway
activation in triple-negative breast cancer is synthetic
lethal with CDK inhibition. J Exp Med 2012;209:679-96.
Hu W, Zhang C, Wu R, et al. Glutaminase 2, a novel p53
target gene regulating energy metabolism and antioxidant
function. Proc Natl Acad Sci U S A 2010;107:7455-60.
Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphateactivated glutaminase (GLS2), a p53-inducible regulator
of glutamine metabolism and reactive oxygen species. Proc
Natl Acad Sci U S A 2010;107:7461-6.
Liu YY. Resuscitating wild-type p53 expression by
disrupting ceramide glycosylation: a novel approach to
target mutant p53 tumors. Cancer Res 2011;71:6295-9.
Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53
disrupts mammary tissue architecture via the mevalonate
pathway. Cell 2012;148:244-58.
Jain S, Wang X, Chang CC, et al. Src inhibition blocks
c-Myc translation and glucose metabolism to prevent the
development of breast cancer. Cancer Res 2015;75:4863-75.
Liu W, Yue F, Zheng M, et al. The proto-oncogene c-Src
and its downstream signaling pathways are inhibited by the
metastasis suppressor, NDRG1. Oncotarget 2015;6:8851-74.
Peglion F, Etienne-Manneville S. p120catenin alteration in
cancer and its role in tumour invasion. Philos Trans R Soc
Lond B Biol Sci 2013;368:20130015.
Gelman IH. The role of SSeCKS/gravin/AKAP12
scaffolding proteins in the spaciotemporal control of
signaling pathways in oncogenesis and development. Front
Biosci 2002;7:d1782-97.
McLaughlin S, Murray D. Plasma membrane
phosphoinositide organization by protein electrostatics.
Nature 2005;438:605-11.
Gelman IH, Gao L. SSeCKS/Gravin/AKAP12 metastasis
suppressor inhibits podosome formation via RhoA- and
Cdc42-dependent pathways. Mol Cancer Res 2006;4:151-8.
Su B, Bu Y, Engelberg D, et al. SSeCKS/Gravin/AKAP12
inhibits cancer cell invasiveness and chemotaxis by
suppressing a protein kinase C- Raf/MEK/ERK pathway. J
Biol Chem 2010;285:4578-86.

© Translational Cancer Research. All rights reserved.

S355

25. Akakura S, Nochajski P, Gao L, et al. Rb-dependent
cellular senescence, multinucleation and susceptibility to
oncogenic transformation through PKC scaffolding by
SSeCKS/AKAP12. Cell Cycle 2010;9:4656-65.
26. Björkblom B, Padzik A, Mohammad H, et al. c-Jun
N-terminal kinase phosphorylation of MARCKSL1
determines actin stability and migration in neurons and in
cancer cells. Mol Cell Biol 2012;32:3513-26.
27. Cohen SB, Waha A, Gelman IH, et al. Expression of a
down-regulated target, SSeCKS, reverses v-Jun-induced
transformation of 10T1/2 murine fibroblasts. Oncogene
2001;20:141-6.
28. Lee SM, Suk K, Lee WH. Myristoylated alanine-rich
C kinase substrate (MARCKS) regulates the expression
of proinflammatory cytokines in macrophages through
activation of p38/JNK MAPK and NF-κB. Cell Immunol
2015;296:115-21.
29. Vogt PK. Fortuitous convergences: the beginnings of
JUN. Nat Rev Cancer 2002;2:465-9.
30. Wilson KF, Erickson JW, Antonyak MA, et al. Rho
GTPases and their roles in cancer metabolism. Trends
Mol Med 2013;19:74-82.
31. Santana SM, Antonyak MA, Cerione RA, et al. Cancerous
epithelial cell lines shed extracellular vesicles with a
bimodal size distribution that is sensitive to glutamine
inhibition. Phys Biol 2014;11:065001.
32. Ono M, Kosaka N, Tominaga N, et al. Exosomes from
bone marrow mesenchymal stem cells contain a microRNA
that promotes dormancy in metastatic breast cancer cells.
Sci Signal 2014;7:ra63.
33. Curi R, Lagranha CJ, Doi SQ, et al. Molecular
mechanisms of glutamine action. J Cell Physiol
2005;204:392-401.
34. Matés JM, Pérez-Gómez C, Núñez de Castro I, et al.
Glutamine and its relationship with intracellular redox
status, oxidative stress and cell proliferation/death. Int J
Biochem Cell Biol 2002;34:439-58.
35. Rhoads JM, Argenzio RA, Chen W, et al. L-glutamine
stimulates intestinal cell proliferation and activates
mitogen-activated protein kinases. Am J Physiol
1997;272:G943-53.
36. Nicklin P, Bergman P, Zhang B, et al. Bidirectional
transport of amino acids regulates mTOR and autophagy.
Cell 2009;136:521-34.
37. Santos AA, Braga-Neto MB, Oliveira MR, et al. Glutamine
and alanyl-glutamine increase RhoA expression and reduce
Clostridium difficile toxin-A-induced intestinal epithelial
cell damage. Biomed Res Int 2013;2013:152052.

tcr.amegroups.com

Transl Cancer Res 2016;5(S2):S349-S356

S356

Dorai et al. Sweetening of glutamine metabolism in cancer cells

38. Davidson SM, Papagiannakopoulos T, Olenchock BA,
et al. Environment impacts the metabolic dependencies
of ras-driven non-small cell lung cancer. Cell Metab
2016;23:517-28.
39. Hensley CT, Faubert B, Yuan Q, et al. Metabolic

heterogeneity in human lung tumors. Cell 2016;164:681-94.
40. Schug ZT, Vande Voorde J, Gottlieb E. The nurture of
tumors can drive their metabolic phenotype. Cell Metab
2016;23:391-2.

Cite this article as: Dorai T, Pinto JT, Cooper AJ. Sweetening
of glutamine metabolism in cancer cells by Rho GTPases
through convergence of multiple oncogenic signaling pathways.
Transl Cancer Res 2016;5(S2):S349-S356. doi: 10.21037/
tcr.2016.07.43

© Translational Cancer Research. All rights reserved.

tcr.amegroups.com

Transl Cancer Res 2016;5(S2):S349-S356

